Neuromodulation-assisted Ego-disengagement: The NEURO-EGO Study Stage 1

Description

The goal of this clinical trial is to learn whether brain stimulation technology can help people reach a meditative state quickly and easily without years of meditation training. The researchers want to see if this will help people distance themselves from their thoughts and feeling, and if this will lead to improvements in openness and wellbeing the same way meditation can. Participants will: * Complete questionnaires * Perform a guided meditation task (The Bell Task) * Wear a high density electrocochleography (hdEEG) cap * Undergo brain stimulation * Perform cognitive tasks

Conditions

Healthy

Talk to us

Study Overview

On this page

Study Details

Study overview

The goal of this clinical trial is to learn whether brain stimulation technology can help people reach a meditative state quickly and easily without years of meditation training. The researchers want to see if this will help people distance themselves from their thoughts and feeling, and if this will lead to improvements in openness and wellbeing the same way meditation can. Participants will: * Complete questionnaires * Perform a guided meditation task (The Bell Task) * Wear a high density electrocochleography (hdEEG) cap * Undergo brain stimulation * Perform cognitive tasks

Neuromodulation-assisted Ego-disengagement: The NEURO-EGO Study

Neuromodulation-assisted Ego-disengagement: The NEURO-EGO Study Stage 1

Condition
Healthy
Intervention / Treatment

-

Contacts and Locations

Madison

University of Wisconsin, Madison, Wisconsin, United States, 53719

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

For general information about clinical research, read Learn About Studies.

Eligibility Criteria

  • * Adults, ages 18 to 55 of any identified gender
  • * Medically healthy
  • * English-speaking (able to provide consent and complete questionnaires)
  • * Healthy adults with a consistent meditation practice
  • * Any current or past history of neurological disorders or acquired neurological disease (e.g. stroke, traumatic brain injury), including intracranial lesions
  • * Any current or past history of bipolar disorder and/or hypomania
  • * Any current or past history of psychosis
  • * History of head trauma resulting in prolonged loss of consciousness; or a history of \>3 grade I concussions
  • * Current history of poorly controlled headaches including intractable or poorly controlled migraines
  • * Any systemic illness or unstable medical condition that may cause a medical emergency in case of a provoked seizure (cardiac malformation, cardiac dysrhythmia, asthma, etc.)
  • * History of fainting spells of unknown or undetermined etiology that might constitute seizures
  • * History of seizures, diagnosis of epilepsy, history of abnormal (epileptiform) EEG, or family history of treatment resistant epilepsy with the exception of a single seizure of benign etiology (e.g. febrile seizures) in the judgment of a board-certified neurologist
  • * Possible pregnancy. All female participants of child-bearing age are required to have a pregnancy test
  • * Any metal in the brain, skull or elsewhere
  • * Any medical devices or implants (i.e. cardiac pacemaker, medication infusion pump, cochlear implant, vagal nerve stimulator, dental implants) unless otherwise approved by the responsible MD
  • * Substance abuse or dependence within the past six months
  • * Any medication that may alter seizure threshold i.e., ADHD stimulants (Adderall, amphetamine); Tricyclic/atypical antidepressants (Amitriptyline, Dioxepine, Imipramine Maprotiline, Nortriptyline, Bupropion); Antipsychotics (Chlorpromazine, Clozapine), Bronchodilators (theophylline, aminophylline); Antibiotics (fluoroquinolones, imipenem, penicillin, cephalosporins, metronidazole, isoniazid); Antiviral (Valacyclovir, Ritonavir); OTC (Diphenhydramine)
  • * Claustrophobia (a fear of small or closed places)
  • * Back problems that would prevent lying flat for up to two hours

Ages Eligible for Study

18 Years to 75 Years

Sexes Eligible for Study

ALL

Accepts Healthy Volunteers

Yes

Collaborators and Investigators

University of Wisconsin, Madison,

Melanie Boly, MD, PhD, PRINCIPAL_INVESTIGATOR, University of Wisconsin, Madison

Study Record Dates

2027-10